Sign in Subscribe

metastatic

A collection of 142 issues

ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery

Skip to content The CRC Digest ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer

Bispecific Antibody EMB-01 Shows Activity in Heavily Pretreated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Bispecific Antibody EMB-01 Shows Activity in Heavily Pretreated Metastatic CRC A phase Ib/II study (NCT05176665) of EMB-01, a novel EGFR × c-MET bispecific antibody, enrolled 52 patients with heavily pretreated metastatic colorectal cancer. EMB-01 was administered at 1600 mg intravenously weekly, with primary

CRC Research Update — August 24, 2026

Today's colorectal cancer research highlights

Synthetic Control Arms From Historical Trial Data May Help Design Future Metastatic CRC Trials

Skip to content The CRC Digest ◆ TRIAL DATA Synthetic Control Arms From Historical Trial Data May Help Design Future Metastatic CRC Trials Researchers used the ARCAD database to construct external control arms from historical trial data for seven landmark metastatic colorectal cancer trials, evaluating whether this approach could complement traditional

CRC Research Update — August 23, 2026

Today's colorectal cancer research highlights

Chemotherapy rechallenge shows activity in late-line metastatic disease

Skip to content The CRC Digest ◆ TRIAL DATA Chemotherapy rechallenge shows activity in late-line metastatic disease A phase II trial found that patients with refractory metastatic colorectal cancer who had previously responded to a regimen for at least 4 months could benefit from rechallenge with the same chemotherapy, with or

Study compares biologic agents in liver-limited RAS wild-type disease

Skip to content The CRC Digest ▸ TREATMENT Study compares biologic agents in liver-limited RAS wild-type disease A retrospective analysis of 241 patients with RAS wild-type metastatic colorectal cancer confined to the liver compared outcomes among patients treated with first-line chemotherapy plus panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective

Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer In a study of 1,391 patients, those with persistent or acquired RAS and BRAF mutations in ctDNA had significantly worse overall survival than patients who maintained wild-type status, suggesting liquid biopsy monitoring

CRC Research Update — August 22, 2026

Today's colorectal cancer research highlights

RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC

Skip to content The CRC Digest ▸ TREATMENT RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC A case report describes a patient with RAF1 S257L-mutated, anti-EGFR-refractory metastatic CRC who achieved radiographic response and performance status improvement with avutometinib (RAF/MEK clamp inhibitor) plus cetuximab. (Oncologist) This content